Market Spotlight: Migraine
Market Spotlight: Migraine
$1,318.00
This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
KEY TAKEAWAYS
- Datamonitor Healthcare estimates that in 2019, there were 554.6 million prevalent cases of migraine in adults aged 20 years and older worldwide, and forecasts that number to increase to 619.8 million prevalent cases by 2028.
- Latin America and the Caribbean is estimated to have the highest disease prevalence (16.4%), while the Northern America region has the lowest prevalence (9.7%).
- The majority of approved drugs in the migraine space target the serotonin 5-HT1 receptor or calcitonin gene-related peptide/receptor. These are commonly administered via the oral route, with a smaller number of products being available in intravenous, intranasal, intramuscular, intradermal, intraarticular, intravesical, rectal, sublingual, oral transmucosal, and subcutaneous formulations.
- There are equal proportions of industry-sponsored drugs in active clinical development for migraine in Phase II and Phase III, with three drugs in the NDA/BLA stage.
- Drugs in development for migraine focus on a wide variety of targets. Approximately half of the drugs in development for migraine are administered via the oral route, with the remainder being intranasal, inhaled, subcutaneous, topical, transdermal, sublingual, and oral transmucosal formulations.
- High-impact upcoming events for drugs in the migraine space comprise topline Phase III trial results for atogepant, STS101, and Vyepti; topline Phase IIIb trial results for Vyepti; topline Phase II trial results for TRV250; an estimated PDUFA date for Qtrypta; and a response to a complete response letter for Rizaport.
- The overall likelihood of approval of a Phase I migraine and other headaches asset is 16.9%, and the average probability a drug advances from Phase III is 94.4%. Drugs, on average, take 7.7 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for migraine have been in the early and mid-phases of development, with 54% of trials in Phase I–II, and 46% in Phase III–IV.
- The US has a substantial lead in the number of migraine clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the migraine space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for migraine, with 95 trials.
- GlaxoSmithKline leads the industry sponsors with by far the highest overall number of clinical trials for migraine, followed by AbbVie and Eli Lilly.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Migraine without aura
8 Migraine with aura
9 TREATMENT
9 Analgesics
9 NSAIDs
9 Serotonergic drugs
10 CGRP inhibitors
10 Prophylactic agents for migraine
11 EPIDEMIOLOGY
14 MARKETED DRUGS
20 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 INP-104 for Migraine (June 10, 2020)
28 AXS-07 for Migraine (April 6, 2020)
30 NURTEC ODT for Migraine (March 30, 2020)
32 AXS-07 for Migraine (December 30, 2019)
34 Vazegepant for Migraine (December 17, 2019)
35 Emgality for Migraine (August 5, 2019)
38 KEY UPCOMING EVENTS
39 KEY REGULATORY EVENTS
39 Cipla Gets CGT Nod For US Migranal Rival
39 Biohaven Goes All In On ODT With Nurtec
39 Dr Reddy’s Elyxyb Receives US Approval For Its NDA
39 FDA Issues Response Letter For Rizaport
39 Relief For Migraine as England’s NICE Reverses Ajovy Knockback
40 Yes For Shionogi But No For Lilly In Latest EMA Recommendations
40 Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine
40 Pricing Could Help Lundbeck’s Vyepti In Slow-Growing CGRP Market
41 Triptan Switches Offer Hope For Australia’s OTC Market
41 Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
41 Lilly Expands Migraine Franchise With Reyvow Approval
41 IntelGenx Takes A Fourth Try At Rizaport Approval
42 Global Device Approvals Snapshot: 9–15 July 2019
42 CGRP Inhibitor Review Pipeline Grows With Biohaven’s Rimegepant Submission
43 PROBABILITY OF SUCCESS
44 LICENSING AND ASSET ACQUISITION DEALS
44 Currax Gains NA License To Optinose’s Onzetra Xsail Migraine Treatment
44 Deals Shaping The Medical Industry, October 2019
44 Lundbeck CEO: Alder Buy Will Boost Pipeline
44 Upsher-Smith Completes Acquisition Of Dr Reddy’s Two Migraine Treatments
45 Kurve, Seurat Collaborate On Nasal Spray For Migraines
46 REVENUE OPPORTUNITY
48 CLINICAL TRIAL LANDSCAPE
49 Sponsors by status
50 Sponsors by phase
51 Recent events
52 BIBLIOGRAPHY
52 Prescription information
55 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of migraine, 2019–28
20 Figure 2: Overview of pipeline drugs for migraine in the US
21 Figure 3: Pipeline drugs for migraine, by company
21 Figure 4: Pipeline drugs for migraine, by drug type
21 Figure 5: Pipeline drugs for migraine, by classification
28 Figure 6: INP-104 for Migraine (June 10, 2020): Phase III – STOP-301
30 Figure 7: AXS-07 for Migraine (April 6, 2020): Phase III – INTERCEPT (Early)
32 Figure 8: NURTEC ODT for Migraine (March 30, 2020): Phase II/III – BHV3000-305 (Migraine Prevention)
34 Figure 9: AXS-07 for Migraine (December 30, 2019): Phase III – MOMENTUM (Acute)
35 Figure 10: Vazegepant for Migraine (December 17, 2019): Phase II/III – 201
37 Figure 11: Emgality for Migraine (August 5, 2019): Phase III – CONQUER
38 Figure 12: Key upcoming events in migraine
43 Figure 13: Probability of success in the migraine pipeline
48 Figure 14: Clinical trials in migraine
48 Figure 15: Top 10 drugs for clinical trials in migraine
49 Figure 16: Top 10 companies for clinical trials in migraine
49 Figure 17: Trial locations in migraine
50 Figure 18: Migraine trials status
51 Figure 19: Migraine trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of migraine, 2019–28
13 Table 2: Prevalence proportions of migraine, 2019–28
15 Table 3: Marketed drugs for migraine
23 Table 4: Pipeline drugs for migraine in the US
27 Table 5: INP-104 for Migraine (June 10, 2020)
29 Table 6: AXS-07 for Migraine (April 6, 2020)
31 Table 7: NURTEC ODT for Migraine (March 30, 2020)
32 Table 8: AXS-07 for Migraine (December 30, 2019)
34 Table 9: Vazegepant for Migraine (December 17, 2019)
36 Table 10: Emgality for Migraine (August 5, 2019)
46 Table 11: Historical global sales, by drug ($m), 2015–19
47 Table 12: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Atopic Dermatitis 
Sign up to the